Front Page News
Thank You for a Wonderful 2022 Annual SMA Conference!
Thank you to everyone who attended the 2022 Annual SMA Conference at the Disneyland Hotel in Anaheim, California! It was an impactful weekend of opportunities […]
Read More ›Cure SMA Attends Spring 2022 Conferences to Promote Findings from Industry Collaboration Initiatives
Cure SMA is pleased to announce the participation of scientific leadership in the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 13–16, 2022), […]
Read More ›Check Out Cure SMA’s State of SMA Report
Cure SMA is pleased to announce the launch of its first annual State of SMA report. The purpose of this report is to share highlights […]
Read More ›Cure SMA Announces Major Newborn Screening Milestone with Addition of Two New SMA Screening States
With today’s newborn screening action by Oregon and New Mexico, Cure SMA has reached a major screening milestone for spinal muscular atrophy (SMA), with 97 […]
Read More ›SMA Community Update from Novartis Gene Therapies
We are pleased to share a community update on Novartis Gene Therapies’ Clinical Trial Program.
Read More ›FDA Approves Genentech’s Evrysdi (risdiplam) For Use in Babies Under Two Months with Spinal Muscular Atrophy
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to […]
Read More ›Cure SMA Launches Request for Proposals for SMA Research Projects and Postdoctoral Fellowships
Cure SMA is pleased to announce that we are accepting grant applications for funding of research projects and postdoctoral fellowships, under a competitive review by […]
Read More ›Cure SMA Announces Expanded Phase 7 of SMA Industry Collaboration
Cure SMA is pleased to announce the launch of an expanded Phase 7 of our SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted […]
Read More ›Cure SMA Support Services Now Expanded to Individuals and Families in Puerto Rico
Along with funding SMA research and care, Cure SMA provides thousands of individuals and families with vital support and resources that help people navigate life […]
Read More ›Biohaven Licenses a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA)
Biohaven Pharmaceutical Holding Company Ltd., announced today that it entered into a worldwide license agreement with Bristol Myers Squibb for the development and commercialization rights to […]
Read More ›